The results of these studies suggest that adalimumab may be a reasonable alternative to infliximab in the treatment of uveitis, but no studies have yet compared these agents.49 Until now, adalimumab has mostly been given in cases of failure to respond to other anti-TNF-α agents, or because of convenient administration. This evidence concerns the gene TNF and uveitis.